Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Get Free Report)’s share price gapped up before the market opened on Friday . The stock had previously closed at $17.13, but opened at $17.88. Telix Pharmaceuticals Limited American Depositary Shares shares last traded at $17.77, with a volume of 1,667 shares traded.
Analyst Ratings Changes
A number of brokerages have commented on TLX. William Blair raised shares of Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a research note on Tuesday, November 19th. UBS Group began coverage on Telix Pharmaceuticals Limited American Depositary Shares in a research report on Friday, November 15th. They issued a “buy” rating and a $21.00 price objective for the company.
View Our Latest Stock Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Trading Up 3.8 %
Telix Pharmaceuticals Limited American Depositary Shares Company Profile
Telix Pharmaceuticals Limited is a biopharmaceutical company which focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It involved in developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.
Featured Stories
- Five stocks we like better than Telix Pharmaceuticals Limited American Depositary Shares
- 3 Monster Growth Stocks to Buy Now
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- How to Buy Cheap Stocks Step by Step
- 3 Buy-and-Hold Stocks for Long-Term Growth
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Telix Pharmaceuticals Limited American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telix Pharmaceuticals Limited American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.